Compounds and methods for the characterization of oligonucleotides
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/00
C07H-021/02
C07H-021/04
C12Q-001/68
출원번호
US-0209160
(2005-08-22)
등록번호
US-7427675
(2008-09-23)
발명자
/ 주소
Capaldi,Daniel C.
Gaus,Hans Joachim Josef
Rentel,Claus Andre Frank
Olsen,Philip Dmitri
Kurata,Christine C.
Song,Quanlai
출원인 / 주소
Isis Pharmaceuticals, Inc.
대리인 / 주소
Isis Patent Department
인용정보
피인용 횟수 :
88인용 특허 :
147
초록
The present invention relates to oligonucleotide synthesis. In particular, the present invention provides methods for characterizing samples useful for making oligonucleotides.
대표청구항▼
What is claimed is: 1. A compound of Formula I, II or III: wherein each R1, R2, R3 and R4 is independently a 2'-O--, 3'-O--, or 5'-O--linked nucleoside optionally attached to solid support, a 2'-O--, 3'-O--, or 5'-O--linked oligonucleotide optionally attached to solid support,--NiPr2,--O(CH2)2CN
What is claimed is: 1. A compound of Formula I, II or III: wherein each R1, R2, R3 and R4 is independently a 2'-O--, 3'-O--, or 5'-O--linked nucleoside optionally attached to solid support, a 2'-O--, 3'-O--, or 5'-O--linked oligonucleotide optionally attached to solid support,--NiPr2,--O(CH2)2CN,--OH or--SH, and each G us independently O or S. 2. A compound of Formula IV: wherein each R4, R5 and R6 is independently a 2'-O--, 3'-O--, or 5'-O--linked nucleoside optionally attached to solid support, or a 2'-O--, 3'-O--, or 5'-O--linked oligonucleotide optionally attached to solid support, G is O or S; and wherein at least one of said 2'-O--, 3'-O--, and 5'-O--linked nucleoside further comprises a phosphorus group. 3. A compound of Formula V: wherein R7 and R8 are independently a 2'-O--, 3'-O--, or 5'-O--linked nucleoside optionally attached to solid support, or a 2'-O--, 3'-O--, or 5'-O--linked oligonucleotide optionally attached to solid support,--SH or--OH, Each G is independently O or S, and R2 is H, OH, O-rg wherein rg is a removable protection group, or a 2' substituent. 4. The compound of claim 1, wherein R1, R2, R3 and R4 are--NiPr2, or--O(CH2)2CN. 5. The compound of claim 1, wherein at least one of R1, R2, R3 or R4 is a 2'-O--, 3'-O--, or 5'-O--linked nucleoside optionally attached to solid support or a 2'-O--, 3'-O--, or 5'-O--linked oligonucleotide optionally attached to solid support. 6. The compound of claim 1, wherein at least two of R1, R2, R3 or R4 are 2'-O--, 3'-O--, or 5'-O--linked nucleosides optionally attached to solid support or 2'-O--, 3'-O--, or 5'-O--linked oligonucleotides optionally attached to solid support. 7. The compound of claim 1, wherein at least three of R1, R2, R3 or R4 are 2'-O--, 3'-O--, or 5'-O--linked nucleosides optionally attached to solid support or 2'-O--, 3'-O--, or 5'-O--linked oligonucleotides optionally attached to solid support. 8. The compound of claim 1, wherein R1, R2, R3 and R4 are 2'-O--, 3'-O--, or 5'-O--linked nucleosides optionally attached to solid support or 2'-O--, 3'-O--, or 5'-O--linked oligonucleotides optionally attached to solid support. 9. The compound of claim 1, wherein said 2'-O--, 3'-O--, or 5'-O--linked nucleosides or 2'-O--, 3'-O--, or 5'-O--linked oligonucleotides are not attached to solid support. 10. The compound of claim 2, wherein said 2'-O--, 3'-O--, or 5'-O--linked nucleosides or 2'-O--, 3'-O--, or 5'-O--linked oligonucleotides are not attached to solid support. 11. The compound of claim 3, wherein said 2'-O--, 3'-O--, or 5'-O--linked nucleosides or 2'-O--, 3'-O--, or 5'-O--linked oligonucleotides are not attached to solid support. 12. The compound of claim 1, wherein the purity of said compound is greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 percent. 13. The compound of claim 1, wherein the purity of said compound is greater than 10 percent. 14. The compound of claim 2, wherein the purity of said compound is greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 percent. 15. The compound of claim 2, wherein the purity of said compound is greater than 10 percent. 16. The compound of claim 3, wherein the purity of said compound is greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 percent. 17. The compound of claim 3, wherein the purity of said compound is greater than 10 percent. 18. A compound of Formula VII: wherein: each G1 is, independently, O or S; each G2 is, independently, OH or SH; each G3 is, independently, O, S, CH2, or NH; each G5 is, independently, O, S, CH2, CFH, CF2, or--CH═CH--; each R2' is, independently, H, OH, O-Pg, a 2'-substituent, or together with R4' forms a bridge; each R3' is, independently, H, a substituent, or together with R4' forms a bridge; each R4' is, independently, H, a substituent, or together with R2' forms a bridge, together with R3' forms a bridge, or together with R5' forms a bridge; each q is, independently, 0 or 1; each R5' is, independently, H, a substituent, or together with R4' forms a bridge; each G6 is, independently, O, S, CH2 or NH; G8 is H or a protecting group; each G10 is, independently, OH, O-Pg, a nucleoside, a nucleotide, or a nucleoside linked to a solid support or a nucleoside linked to a conjugate group; Pg is a protecting group; m is an integer from 1 to about 100; n and o are each identical integers from 0 to about 100, provided that when n and o are 0, then each G10 is an independently selected nucleoside linked to a solid support; and each Bx is a naturally occurring or modified nucleobase. 19. The compound of claim 18 wherein each G3 is O or S. 20. The compound of claim 18 wherein each G1 is S.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (147)
Manoharan Muthiah ; Kawasaki Andrew M. ; Cook Phillip Dan ; Fraser Allister S. ; Prakash Thazha P., 2'-O-acetamido modified monomers and oligomers.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), DNA-reporter conjugates linked via the 2′or 5′-primary amino group of the 5′-terminal nucleoside.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Exonuclease resistant terminally substituted oligonucleotides.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent L. (Austin TX) Sansom Petra I. (Austin TX) Crofts Shaun P. (Campbell CA), Method of expanded porphyrin-oligonucleotide conjugate synthesis.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Ravikumar Vasulinga ; Mulvey Dennis ; Cole Douglas L. ; Cook Phillip Dan, Monomeric and dimeric nucleosides with silyl-containing diamino phosphorous linkages.
Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods.
Shizuya Hiroaki (1632 Indiana Ave. South Pasadena CA 91030) Millar Sharon L. (1825 Lanai St. West Covina CA 91792), Non-radioisotope tagging of fragments.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Nguyen Thanh T. (Tigy FRX) Helene Claude (Saint Cyr en Val FRX) Asseline Ulysse (La Source FRX), Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis a.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Nuclease resistant compounds.
Klevan Leonard (Washington DC) Gebeyehu Gulilat (Silver Spring MD) Rao Prasad Y. (Damascus MD), Nucleotide analogs for nucleic acid labeling and detection.
Warren ; III Harold C. (Rush NY) Oakes Fred T. (Rochester NY), Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction proce.
Haralambidis Jim (Box Hill South AUX) Tregear Geoffrey W. (Hawthorn AUX), Oligonucleotide-polyamide conjugates and methods of production and applications of the same.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Meyer ; Jr. Rich B. (Woodinville WA) Gall Alexander A. (Bothell WA) Reed Michael W. (Seattle WA), Peptide linkers for improved oligonucleotide delivery.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Vasulinga T. Ravikumar ; Muthiah Manoharan ; Daniel C. Capaldi ; Achim Krotz ; Douglas L. Cole ; Andrei Guzaev, Process for the synthesis of oligomeric compounds.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA), Texaphyrin metal complexes having improved functionalization.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA) Kral Vladimir A. (Austin TX) Magda Darren (Cupertino CA), Texaphyrin-oligonucleotide conjugates.
Reed Michael W. (3575 NE. 180th Seattle WA 98105) Meyer ; Jr. Rich B. (15411 NE. 176th Pl. Woodinville WA 98072), Trifunctional intermediates for preparing 3′-tailed oligonucleotides.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ).
Collard, Joseph; Khorkova Sherman, Olga, Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ).
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
Faghihi, Mohammad Ali; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS).
Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3).
Collard, Joseph; Khorkova Sherman, Olga, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
Collard, Joseph; Sherman, Olga Khorkova, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; De Leon, Belinda, Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT).
Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda; Coito, Carlos; Hsiao, Jane H., Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
Collard, Joseph; Khorkova Sherman, Olga, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
Collard, Joseph; Sherman, Olga Khorkova, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP.
Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.